Why the study?
While SGLT2 inhibitors improve health status across the left ejection fraction spectrum in heart failure, the effects of combined SGLT1 and SGLT2 inhibition on health status were unknown.
Does sotagliflozin improve heart failure-related health status in patients with type 2 diabetes following a worsening heart failure episode?
Does sotagliflozin improve heart failure-related health status in patients with type 2 diabetes following a worsening heart failure episode?
Sotagliflozin significantly improved symptoms, physical limitations, and quality of life at 4 months in patients with type 2 diabetes following a worsening heart failure event.
Answers are grounded in this paper and cite their sources.
Supports sotagliflozin for modest health status gains after worsening HF in T2D; extends SGLT inhibitor evidence to KCCQ outcomes.
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors improve health status in heart failure (HF) across the left ejection fraction ejection spectrum. However, the effects of SGLT1 and SGLT2 inhibition on health status are unknown. OBJECTIVES: These prespecified analyses of the SOLOIST-WHF (Effect of Sotagliflozin on Cardiovascular Events in Patients with Type 2 Diabetes Post Worsening Heart Failure) trial examined the effects of sotagliflozin vs placebo on HF-related health status. METHODS: SOLOIST-WHF randomized patients hospitalized or recently discharged after a worsening HF episode to receive sotagliflozin or placebo. The primary endpoint was total number of HF hospitalizations, urgent HF visits, and cardiovascular death. Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) score was a prespecified secondary endpoint. This analysis evaluated change in the KCCQ-12 score from baseline to month 4. Sotagliflozin-treated patients vs those receiving placebo experienced modest improvement in KCCQ-12 at 4 months (adjusted mean change: 4.1 points; 95% CI: 1.3-7.0 points; P = 0.005). KCCQ-12 improvements were consistent across prespecified subgroups, including left ventricular ejection fraction <50% or ≥50%. More patients receiving sotagliflozin vs those receiving placebo had at least small (≥5 points) improvements in KCCQ-12 at 4 months (OR: 1.38; 95% CI: 1.06-1.80; P = 0.017). CONCLUSIONS: Sotagliflozin improved symptoms, physical limitations, and quality of life within 4 months after worsening HF, with consistent benefits across baseline demographic and clinical characteristics. (Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure [SOLOIST-WHF]; NCT03521934).
No takes yet. Share an insight, caveat, or question.
Bhatt et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: